The effect of Aspirin on Schizophrenia; a Double Blind Placebo Controlled Study. | [Journal of Islamic International Medical College • 2017]

Author(s):

1. Hamidreza Jamilian: Department of Psychiatry Arak University of Medical Sciences, Arak, Iran

2. Gevick Hacoupian: Department of Psychiatry Arak University of Medical Sciences, Arak, Iran

Abstract:

Objective: To determine the beneficial antipsychotic effects of aspirin plus atypical antipsychotic agents in the treatment of schizophrenia. Study Design: A double blind placebo controlled study. Place and Duration of Study: The study was conducted in Psychiatry ward of Imam Reza and Shahid Hashemi Mental Hospital in Arak, from April to December 2011. Materials and Methods: This double blind placebo controlled study was conducted on 60 patients with schizophrenia. Patients were assigned to case group who received an atypical antipsychotic agent (olanzapine, risperidone, clozapine) as the standard treatment of the schizophrenia plus aspirin 1000 mg /daily (aspirin or case group n=30), and 30 patients received standard treatment and placebo (control group, n=30). The PANSS questionnaire was used to evaluate patients at 0, 2,4,6 and 8 weeks after treatment. SPSS software was used for data analysis. Student's t-test was applied and repeated measurement test to compare two groups Results: The difference between two groups regarding positive and negative symptoms was not significant (Repeated Measure/P=0.20 and P =0.20 respectively). However, there was a significant difference between two groups regarding general and total symptoms (Repeated Measure/P=0.003 and P=0.032 respectively). The results did not show any remarkable related side effects to aspirin in two groups. Conclusion: The trial revealed that aspirin 1000 mg /day in combination with antipsychotic drugs for 8 weeks is an effective agent for the reduction of general and total symptoms of schizophrenia. Nonetheless, it did not modify the positive and negative symptoms.

Page(s): 168-172

DOI: DOI not available

Published: Journal: Journal of Islamic International Medical College, Volume: 12, Issue: 4, Year: 2017

Keywords:

Keywords are not available for this article.

References:

[1] SchizophreniaFact, 2015.,World Health Organisation September -

[2] SimpsonEH,KellendonkC,KandelE., 2010.A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia,Neuron 65 585 -96

[3] DawsonME,SchellAM,RisslingA,VenturaJ,SubotnikKL,NuechterleinKH, 2010.Psychophysiological prodromal signs of schizophrenic relapse: a pilot study,Schizophr. Res 123 64 -7

[4] ColemanMJ,CestnickL,KrastoshevskyO,KrauseV,HuangZ,MendellNR, 2009.Schizophrenia patients show deficits in shifts of attention to different levels of global-local stimuli: evidence for magnocellular dysfunction,Schizophr. Bull 35 1108 -16

[5] ChangBP,LenzenwegerMF, 2005.Somatosensory processing and schizophrenia liability: proprioception, exteroceptive sensitivity, and graphesthesia performance in the biological relatives of schizophrenia patients,J. Abnorm. Psychol 114 85 -

[6] ChenY., 2011.Abnormal visual motion processing in schizophrenia: a review of researchprogress,Schizophr. Bull 37 709 -15

[7] HowesOD,PoliFP,BloomfieldM,SelvarajS,McGuireP, 2012.From the prodrome to chronic schizophrenia: the neurobiology underlying psychotic symptoms and cognitive impairments,Curr Pharm Des 18 459 -65

[8] MillerBJ,BuckleyP,SeaboltW,MellorA,KirkpatrickB, 2011.Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects,Biol Psychiatry 70 663 -71

[9] GirgisRR,KumarSS,BrownAS, 2014.The cytokine model of schizophrenia: emerging therapeutic strategies,Biol Psychiatry 75 292 -9

[10] FanX,LiuEY,FreudenreichO,ParkJH,LiuD,WangJ, 2010.Higher white blood cell counts are associated with an increased risk for metabolic syndrome and more severe psychopathology in nondiabetic patients with schizophrenia,Schizophr Res 118 211 -7

[11] MirhafezSR,MohebatiM,DisfaniFM,KarimianSM,EbrahimiM,AvanA, 2014.Cytokines and C-reactive protein alterations with respect to cognitive impairment in schizophrenia and bipolar disorder: a systematic review, 8 614 -23

[12] SommerIE,Van WestrhenenR,BegemannMJ,de WitteLD,LeuchtS,KahnRS, 2014.Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update,Schizophr Bull 40 181 -91

[13] .Diagnostic and Statistical Manual of Mental Disorders (5th ed,Arlington: American Psychiatric Publishing. ISBN 978-0890425558. -

[14] BrownAS,DerkitsEJ, 2010.Prenatal infection and schizophrenia: a review of epidemiologic and translational studies,Am J Psychiatry 167 261 -80

[15] BrownAS,HootonJ,SchaeferCA,ZhangH,PetkovaE,BabulasV, 2004.Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring,Am J Psychiatry 161 889 -95

[16] SirotaP,SchildK,ElizurA,DjaldettiM,FishmanP, 1995.Increased interleukin- 1 and interleukin-3 like activity in schizophrenic patients,Prog Neuropsychopharmacol Bio Psychiatry 19 75 -83

[17] LicinioJ,SeibylJP,AltemusM,CharneyDS,KrystalJH, 1993.Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients,Am J Psychiatry 150 1408 -10

[18] McAllisterCG,van KammenDP,RehnTJ,MillerAL,GurklisJ,KelleyME, 1995.Increases in CSF levels of interleukin- 2 in schizophrenia: effects of recurrence of psychosis and medication status,Am J Psychiatry 152 1291 -7

[19] AidS, 2011.Targeting cyclooxygenases-1 and -2 in neuroinflammation: Therapeutic implications,Biochimie 93 46 -51

[20] LaanW,GrobbeeDE,SeltenJP,HeijnenCJ,KahnRS,BurgerH, 2010.Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial,J Clin Psychiatry 71 520 -7

[21] MullerN,RiedelM,ScheppachC,BrandstätterB,SokulluS,KrampeK, 2002.Beneficial Antipsychotic Effects of Celecoxib Add-On Therapy Compared to Risperidone Alone in Schizophrenia,Am J Psychiatry 159 1029 -34

[22] MullerN,UlmschneiderM,ScheppachC, 2004.COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy,Eur Arch Psychiatry Clin Neurosci 254 14 -22

[23] MullerN,KrauseD,DehningS,MusilR,WolffSR,ObermeierM, 2010.Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment,Schizophr Res 121 118 -24

[24] AkhondzadehS,TabatabaeeM,AminiH,Ahmadi AbhariSA,AbbasiSH,BehnamB, 2007.Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebocontrolled trial,Schizophr Res 90 179 -85

Citations

Downloads

Views